Longevity Health reports unaudited Q1 revenue $663,000, up 8% year-over-year
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2025
0mins
Should l Buy ?
Merger and Financial Updates: Longevity Health has entered a merger agreement with 20/20 BioLabs, expected to close soon, while reporting Q1 sales increases for both companies. A reverse stock split was completed on May 12, 2025.
Product Launches and Initiatives: XAGE plans to launch a medicated cleanser targeting physicians and MedSpas, while 20/20 will introduce a lab test for inflammatory biomarkers and expand its partnership with Giant Food for cancer testing.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
